Kinetic Estimation of GFR Improves Prediction of Dialysis and Recovery after Kidney Transplantation by Pianta, T. J. et al.
RESEARCH ARTICLE
Kinetic Estimation of GFR Improves
Prediction of Dialysis and Recovery after
Kidney Transplantation
Timothy J. Pianta1,2*, Zoltan H. Endre1,3, JohnW. Pickering3, Nicholas A. Buckley4,
Philip W. Peake1
1 Prince of Wales Clinical School, University of New South Wales, Sydney, Australia, 2 Melbourne Medical
School, University of Melbourne, Melbourne, Australia, 3 Department of Medicine, University of Otago,
Christchurch, New Zealand, 4 Clinical Pharmacology, University of Sydney, Sydney, Australia
* timothy.pianta@nh.org.au
Abstract
Background
The early prediction of delayed graft function (DGF) would facilitate patient management
after kidney transplantation.
Methods
In a single-centre retrospective analysis, we investigated kinetic estimated GFR under non-
steady-state conditions, KeGFR, in prediction of DGF. KeGFRsCr was calculated at 4h, 8h
and 12h in 56 recipients of deceased donor kidneys from initial serum creatinine (sCr) con-
centrations, estimated creatinine production rate, volume of distribution, and the difference
between consecutive sCr values. The utility of KeGFRsCr for DGF prediction was compared
with, sCr, plasma cystatin C (pCysC), and KeGFRpCysC similarly derived from
pCysC concentrations.
Results
At 4h, the KeGFRsCr area under the receiver operator characteristic curve (AUC) for DGF
prediction was 0.69 (95% CI: 0.56–0.83), while sCr was not useful (AUC 0.56, (CI: 0.41–
0.72). Integrated discrimination improvement analysis showed that the KeGFRsCr improved
a validated clinical prediction model at 4h, 8h, and 12h, increasing the AUC from 0.68
(0.52–0.83) to 0.88 (0.78–0.99) at 12h (p = 0.01). KeGFRpCysC also improved DGF predic-
tion. In contrast, sCr provided no improvement at any time point.
Conclusions
Calculation of KeGFR from sCr facilitates early prediction of DGF within 4 hours of
renal transplantation.
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Introduction
Calculation of a non-steady state (kinetic) glomerular filtration rate, the KeGFR, has recently
been advocated in assessment of acute kidney injury (AKI) and renal recovery [1]. The formula
is derived from the change in consecutive values of serum creatinine (sCr), and the estimated
creatinine production rate and volume of distribution (Vd) to estimate GFR. This approach to
characterising clearance is adaptable to alternative circulating filtration biomarkers including
cystatin C (CysC) [1].
Twenty to thirty percent of deceased donor kidneys and approximately half of kidneys do-
nated after cardiac death develop delayed graft function (DGF), defined as requirement for di-
alysis within the first week after transplantation [2]. DGF is associated with increased rates of
rejection and graft loss, inferior graft function and increased length of hospital stay [3]. Early
identification of patients with DGF is already important in modifying standard immunosup-
pressive and antimicrobial (cytomegalovirus and Pneumocystis jirovecii) prophylaxis after
transplantation. Thus avoidance or reduction in the dose of standard but potentially nephro-
toxic immunosuppressive therapy with calcineurin-inhibitors, tacrolimus or cyclosporine, and
a reduction in doses of valgan- or vala-ciclovir and of co-trimoxazoles is essential in DGF. In
addition, while there have been no clinical studies demonstrating successful intervention to
prevent acute tubular injury or accelerate recovery so far, rapid identification of DGF may facil-
itate intervention when appropriate agents eventually become available [4,5]. However, current
methods for prediction of DGF after kidney transplantation are unreliable.
While the presence of anuria is a specific sign of DGF, it is not sensitive [6], and change in
sCr is an unreliable marker of DGF for the first 24 hours after transplantation [5,7]. Immedi-
ately after transplantation, sCr is influenced by many factors including residual renal function,
pre-transplant dialysis and peri-operative fluid administration [4] and is known to be a poor
predictor of DGF [7]. A clinical prediction model has been developed with an online calculator
to predict DGF from donor-, recipient-, and transplant-related variables [8]. While this model
has been validated [9], its diagnostic utility for predicting DGF in two cohorts has been only
“fair” [10] with areas under the receiver operator characteristic curve (AUCs) of 0.70 [8] and
0.71 [9]. This risk assessment is fixed once transplantation has occurred, so injury signals after
transplantation are not incorporated and cannot enhance prediction of DGF.
An alternative circulating filtration marker is plasma cystatin C (pCysC). pCysC is pro-
duced by all nucleated cells at a near constant rate, does not re-circulate after glomerular fil-
tration nor undergo tubular secretion [11]. While pCysC is subject to similar perioperative
influences as sCr, CysC is only distributed in extracellular fluid (ECF) [4,11,12], rather than
total body water (TBW). With one-third the Vd of creatinine, pCysC reaches a new steady
state three times more rapidly than sCr after GFR is perturbated [4]. Several studies have
recognized that pCysC outperforms sCr for DGF prediction and advocated for pCysC to
replace sCr [7,13].
Using sCr [14] or pCysC [15] under steady-state conditions GFR can be estimated using
formulae that adjust for age, race and sex. The Cockroft-Gault formula [16] adjusts for age, sex
and weight to estimate creatinine clearance (CrCl). However, these formulae and the classic
equation for CrCl are invalid under non-steady state conditions such as occur after transplan-
tation [4]. CysC clearance cannot be measured in healthy kidneys directly because of tubular
uptake and lysosomal metabolism of filtered CysC [4,11,17].
We hypothesised that calculation of KeGFR would improve the prediction of DGF indepen-
dently of a validated clinical risk prediction model [8]. We also hypothesised that pCysC and
KeGFR derived from pCysC would predict DGF better than sCr-based estimates. These hy-
potheses were evaluated in a retrospective analysis of prospectively studied renal transplant
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recipients in which calculation of KeGFR from sCr facilitated early prediction of DGF within 4
hours of renal transplantation.
Subjects and Methods
The study was conducted under institutional Human Ethics Committee approval
(EC00134:10/113), in adherence to the Declaration of Helsinki and the principles outlined in
the ‘Declaration of Istanbul on Organ Trafficking and Transplant Tourism’. Specifically, none
of the transplant donors were from a vulnerable population and all donors or next of kin pro-
vided written informed consent that was freely given.
We performed a retrospective analysis of previously published prospectively acquired sCr
and pCysC data [6]. Consecutive eligible patients aged 18 years or older undergoing deceased
donor kidney transplantation between 2011 and 2013 at Prince of Wales Hospital, Sydney
were approached for inclusion. Clinical decisions regarding patient treatment, including dialy-
sis were made independently by treating physicians. Patients received a uniform protocol of
corticosteroids, basiliximab, and mycophenolate sodium, and tacrolimus or cyclosporine at the
treating physician’s discretion.
Samples
sCr was measured immediately after organ reperfusion as part of routine care. Additional
blood samples were collected at 4h, 8h and 12h after organ reperfusion for the study. Blood
was immediately centrifuged and serum and plasma was aliquoted and stored at -80°C prior to
batched assay.
Assays
sCr was measured using enzymatic methods on an automated chemical analyser (Konelab
20XT, Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer’s recommen-
dations. CysC was measured using microparticle-enhanced immunoturbidometric methods
using the same analyser and a calibrator (X791201, Dako, Glostrup, Denmark) traceable to the
International Federation of Clinical Chemistry Working Group certified reference material
(ERM-DA471/IFCC) [18].
Variables examined
The primary outcome was DGF, defined as the need for dialysis within 1 week of transplanta-
tion [3]. The predictive utility of sCr, pCysC, unadjusted (steady-state) eGFR derived from sCr
and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [14]
(eGFRsCr), unadjusted eGFR derived from pCysC and the CKD-EPI formula [15] (eGFRpCysC),
and KeGFR using sCr (KeGFRsCr) for DGF was assessed at 4h, 8h and 12h, and KeGFR using
pCysC (KeGFRpCysC) assessed at 8 and 12h.
KeGFR was calculated using the formula [1]:
KeGFR ¼ BC  eGFR
MeanBc
 1 24  DBC
Dt  MaxDBC=d
 
Bc × eGFR is the circulating biomarker concentration (Bc, sCr or pCysC) multiplied by the
corresponding unadjusted eGFR [14,15]; MeanBc is the mean of two consecutive values of Bc
(e.g. at 4h and 8h); ΔBc is the difference between each two values; Δt is the interval between
samples (hours), and MaxΔBc/d is the maximal theoretical increase in sCr or pCysC in 1 day
when GFR is zero.
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Two values must be determined: i) Bc×eGFR and ii) MaxΔBc/d. Assuming mass balance
principles [1,19] these 2 terms are closely related [1]:
a. Bc×eGFR is proportional to daily circulating biomarker production, and
b. MaxΔBc/d equals daily circulating biomarker production divided by Vd,
To convert Bc×eGFR [e.g. sCr (μmol/L) × eGFR (mL/min/1.73m
2)] to daily circulating
biomarker production (μmol/d/1.73m2) a conversion factor of 1.44 accounted for the 1440
minutes per day and 1000 millilitres per litre. Bc×eGFR is expressed in μmol/d/1.73m
2 or
mg/d/1.73m2 and KeGFR is expressed in mL/min/1.73m2, however to avoid unwieldy terms,
we have omitted further referring to body surface area in subsequent discussion.
The CKD-EPI formula was used for eGFR estimation using both creatinine [14] and CysC
[15], i.e., in both the “Bc×eGFR” and “MaxΔBc/d” terms. As suggested [1] Bc×eGFR was calcu-
lated once for the entire acute renal episode and, for consistency, the 4h value of sCr or pCysC
was used. Thus,
Daily circulatingbiomarkerproduction ¼ Bc 4hð Þ  eGFR  1:44
and
MaxDBc=d ¼ Bc 4hð Þ  eGFR  1:44=Vd
For sCr, estimated Vd = 0.6 × body weight (kg) [1,20]. For pCysC, estimated Vd =
0.2 × body weight (kg) [12].
Because eGFR cannot be less than 0, a value of 0 was assigned to any negative calculated
value of KeGFR.
Statistical analysis
Analyses were conducted with Prism v6.0 (GraphPad, La Jolla, CA) and MATLAB 2012b
(Mathworks, Natick, MA). Because dialysis modifies sCr and pCysC, after initiation of dialysis,
patients were excluded from analysis at subsequent timepoints.
Performance in prediction of DGF was assessed from the AUC calculated at each timepoint
and comparisons made using the DeLong method [21]. Optimal cut-offs were values with the
maximal Youden index [22]. KeGFR represents the arithmetic mean of estimated GFR between
two timepoints. For example, the KeGFRsCr calculated at 4h most closely estimated eGFR at 2h
(i.e. the midpoint between 0h and 4h). Since the second value of sCr required for this calcula-
tion was unavailable until 4h, its performance was evaluated against the 4h sCr. Agreement be-
tween different eGFR and KeGFR estimates was assessed using Bland-Altman analysis.
The baseline model used the published [8] and validated [9] risk prediction model for DGF.
Individual DGF risk was calculated online (http://www.transplantcalculator.com) after enter-
ing 9 recipient-, 8 donor-, and 3 transplantation-related factors as described [8] (Table 1). Inte-
grated discrimination improvement (IDI) analysis was used to determine the enhancement
added by each variable to this model. Multivariable logistic regression with forward entry was
used to construct models by alternately adding variables to the reference score and calculating
the probability of DGF for each patient. IDIs were calculated for each variable to determine the
mean increase in calculated risk for those who developed DGF (IDI-DGF), and reduction for
those who did not (IDI-non-DGF) after the addition of the variable to the baseline score [23].
Sensitivity analyses evaluated alternative assumptions of creatinine and CysC production.
(S2 Table). MaxΔsCr/d was alternatively estimated using the Cockroft-Gault formula [16], and
a fixed value (235 mmol/L/d, i.e. 3mg/dL/d a moderately high estimate of MaxΔsCr/d in anuric
AKI) [1,24] for all patients, while MaxΔpCysC/d was alternatively estimated using the Sjostrom
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Table 1. Baseline characteristics of transplant recipients and donors.
Total, n = 56 Non-DGF, n = 34 DGF, n = 22 p value
Recipient Characteristics
Malea, n (%) 21 (62) 15 0.78
Agea, years 56 (49–62) 50 (47–62) 0.76
Age < 16 yearsb 0 0
Ethnicity, n (%)
Black Africana 0 0
Caucasian 22 (65) 17 (77) 0.38
Non-Caucasian 12 (35) 5 (23)
Asian 10 (29) 2 (9)
Paciﬁc Islander 2 (6) 1 (4)
Other 0 2 (9)
Body mass index (kg/m2)a, median (IQR) 25 (23–28) 30 (25–33) 0.05
% Peak PRAa, median (IQR) 3 (1–11) 10 (3–39) 0.12
Duration of dialysisa (months),median (IQR) 64 (31–84) 75 (35–91) 0.46
Previous transplanta (yes), n (%) 3 (8) 5 (23) 0.24
Pretransplant transfusiona (yes), n (%) 7 (21) 6 (27) 0.74
Diabetes mellitusa, n (%) 5 (14) 6 (27) 0.31
Extrarenal transplantb, n 0 0
Hemodialysisc 28 (82) 20 (91) 0.46
Induction regimen
Calcineurin Inhibitor
Tacrolimus 26 (74) 17 (81) 1.00
Cyclosporine A 8 (24) 5 (23)
Deceased Donor Characteristics n = 34d n = 22d
Male, n (%) 18 (53) 11 (50) 1.00
Agea, years (IQR) 54 (41–65) 56 (43–61) 0.78
Cardiac Deatha, n (%) 2 (6) 9 (41) 0.002
ECD, n (%) 8 (23) 3 (14) 0.50
Terminal sCra, μmol/L (IQR) 81 (60–95) 61 (56–82) 0.10
Cause of death, n (%)
Strokea 14 (41) 10 (45) 0.79
Anoxiaa 3 (9) 2 (9) 1.00
Transplant Characteristics
HLA mismatchesa, median (IQR) 4 (2–5) 4 (2–6) 0.54
Ischaemia time (min), median (IQR)
Colda 531 (408–787) 708 (514–997) 0.04
Warma 43 (34–52) 47 (32–67) 0.68
Machine Perfusionb 0 0
Key:
a: all others peritoneal dialysis
b: all others rabbit anti-thymocyte globulin
c: No donor contributed a kidney to more than one recipient within the cohort
DGF: Delayed Graft Function, Non-DGF: Non-Delayed Graft Function,
ESKD: End Stage Kidney Disease; ECD: Expanded Criteria Donor; sCr: serum creatinine.
doi:10.1371/journal.pone.0125669.t001
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formula [12], and a fixed value (3 mg/L/d) [1] (S2 Table). Expression of KeGFR in mL/min (i.e.
KeGFR × BSA / 1.73) was also evaluated (S3 Table). The inclusion of recipients of live-donor
kidneys concurrently recruited was assessed in a further sensitivity analyses (S4 Table).
Results
56 recipients of deceased-donor kidney transplants were consented for inclusion. Patient char-
acteristics are shown in Table 1. After transplantation, four patients commenced dialysis be-
tween 4h and 8h, leaving 52 patients for analysis at 8h and 12h (Table 2). No patient was
dialysed for isolated hyperkalaemia and there were no cases of primary non-function.
Circulating biomarkers, eGFR and KeGFR: univariable analysis
sCr, pCysC, eGFRsCr, eGFRpCysC, KeGFRsCr, and KeGFRpCysC for each patient are presented in
Fig 1; the latter four are compared in Fig 2. AUCs for prediction of DGF are presented in Fig 3.
KeGFRsCr predicted DGF at all time points with higher AUC values than sCr, and these dif-
ferences were statistically significant at 12h (Fig 3A).
pCysC also predicted DGF at all time points with higher AUC values than sCr; the differ-
ence significant only at 4h (Fig 3B).
KeGFRpCysC predicted DGF with higher AUC values than sCr at both 8h and 12h but the
improvement was not significant at either time. There was no significant difference between
KeGFRpCysC and pCysC at either 8h or 12h (Fig 3B).
eGFRsCr performed no better for prediction of DGF than sCr alone (Fig 3A), and eGFRpCysC
performed no better for prediction of DGF than pCysC alone at any time (Fig 3B).
Table 2. Prediction of DGF using KeGFR versus the clinical model.
Variables AUC (95% CI) p IDI-DGF (95% CI) IDI-Non-DGF (95% CI)
Base Model 4h (n = 56) 0.72 (0.58 to 0.86) a a
Base Model + sCr 0.73 (0.59 to 0.87) 0.79 0.01 (-7 x 10–4 to 0.07) 0.01 (-4 x 10–4 to 0.05)
Base Model + KeGFRsCr 0.77 (0.63 to 0.89) 0.24 0.03 (1 x 10–6 to 0.11)b 0.02 (3 x 10–5 to 0.08)b
Base Model + pCysC 0.77 (0.64 to 0.90) 0.13 0.02 (-5 x 10–5 to 0.11) 0.02 (-1 x 10–5 to 0.08)
Base Model 8h & 12h (n = 52) 0.68 (0.52 to 0.83)
8h (n = 52)
Base Model + sCr 0.67 (0.52 to 0.83) 0.39 0.00 (-0.004 to 0.004) 0.00 (-0.001 to 0.002)
Base Model + KeGFRsCr 0.81 (0.67 to 0.94) 0.16 0.07 (9 x 10–4 to 0.21)b 0.04 (6 x 10–4 to 0.12)b
Base Model + pCysC 0.78 (0.65 to 0.92) 0.10 0.03 (-5 x 10–4 to 0.14) 0.02 (-2 x 10–4 to 0.09)
Base Model + KeGFRpCysC 0.78 (0.64 to 0.92) 0.19 0.06 (2 x 10–4 to 0.20)b 0.04 (0.15 to 0.12)b
12h (n = 52)
Base Model + sCr 0.71 (0.56 to 0.86) 0.32 0.01 (-0.004 to 0.06) 0.00 (-0.001 to 0.03)
Base Model + KeGFRsCr 0.88 (0.78 to 0.99) 0.01b 0.18 (0.04 to 0.35)b 0.10 (0.03 to 0.21)b
Base Model + pCysC 0.80 (0.67 to 0.93) 0.11 0.06 (-8 x 10–4 to 0.19) 0.03 (-2 x 10–4 to 0.11)
Base Model + KeGFRpCysC 0.82 (0.69 to 0.95) 0.09 0.11 (0.02 to 0.25)b 0.06 (0.01 to 0.15)b
Model enhancement was analysed by calculation of the IDI. The clinical base model was derived from recipient-, donor- and transplant related factors
(reference [8]). There is no KeGFRpCysC at 0–4h since no 0h pCysC data were available.
Key:
a: metrics are not calculable for baseline model alone
b: p < 0.05 vs. base model; IDI: integrated discrimination improvement.
doi:10.1371/journal.pone.0125669.t002
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Integrated discrimination improvement (IDI) analysis
Incorporation of KeGFRsCr independently improved prediction of DGF at 4h [average increase
in calculated risk of DGF (IDI-DGF): 0.03 (95% CI: 1 x 10–6 to 0.11)] and non-DGF [IDI-non-
DGF: 0.02 (95% CI: 3 x 10–5 to 0.08)] (Table 2) with the AUC for the new model increasing
Fig 1. Serum creatinine, plasma cystatin C, unadjusted eGFR and kinetic estimated GFR for each
patient. Values for each patient of (A) serum creatinine (sCr), (B) unadjusted estimate of GFR using sCr
(eGFRsCr), (C) kinetic estimate of GFR using sCr (KeGFRsCr), (D) plasma cystatin C (pCysC), (E) unadjusted
estimate of GFR using pCysC (eGFRpCysC), and (F) kinetic estimate of GFR using pCysC (KeGFRpCysC).
Results are stratified for patients developed delayed graft function, i.e. dialysis requirement within 7 days
(red) and those who did not (black). Red squares represent patients who were dialysed before the next
timepoint. There is no KeGFRpCysC at 0–4h since no 0h pCysC data were available.
doi:10.1371/journal.pone.0125669.g001
Fig 2. KeGFR versus eGFR, and KeGFRsCr vs. KeGFRpCysC. A—C: Unadjusted eGFRsCr and KeGFRsCr values stratified for DGF (red) or Non-DGF
(black) at 4h (A), 8h (B), and 12h (C). D: Bland-Altman Plot comparing eGFR and KeGFR at 4h (blue triangles), 8h (open squares), and 12h (red circles) after
kidney transplantation. Dotted line represents bias (mean difference between parameters); dashed lines represent 95% limits of agreement. E and F: Values
for each patient of eGFRpCysC and KeGFRpCysC stratified for DGF or Non-DGF at 8h (E) and 12h (F) G: Bland-Altman Plot comparing eGFR and KeGFR at 8h
and 12h after kidney transplantation. H: Bland-Altman Plot comparing KeGFRsCr and KeGFRpCysC at 8h and 12h after kidney transplantation. There was no
KeGFRpCysC determined at 4h since no 0h pCysC data were available. #: p 0.05, * p < 0.05.
doi:10.1371/journal.pone.0125669.g002
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Fig 3. KeGFR prediction of DGF compared with unadjusted eGFR and sCr. A: estimated kinetic GFR
using serum creatinine (KeGFRsCr) compared with serum creatinine (sCr) and unadjusted estimate of GFR
using sCr (eGFRsCr). Figures show area under receiver operator characteristic curve (AUC) and 95%
confidence intervals for prediction of DGF at 4h (n = 56), 8h (n = 52) and 12h (n = 52). Asterisk (*) denotes
p < 0.05 for the comparison with the AUC for sCr at the same time.
doi:10.1371/journal.pone.0125669.g003
Kinetic eGFR for DGF and Graft Recovery
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from 0.72 to 0.77 (95% CI: 0.63–0.89). Enhancement of the clinical model with KeGFRsCr was
also seen at 8h and 12h (Table 2, Fig 4).
Risk assessment plots (see reference [22]) for the base model, (dotted lines) and models
after addition of variables (solid lines). Red lines are sensitivity versus the calculated risk for pa-
tients who developed delayed graft function. Black lines represent 1-specificity versus the calcu-
lated risk for those who did not have delayed graft function. Improved risk assessment is
demonstrated by movement of the red curve to the top-right corner and black curve to the bot-
tom left corner after addition of a biomarker.
KeGFRpCysC performed similarly to KeGFRsCr improving the prediction of DGF at both 8h
and 12h (Table 2, Fig 4) although the quantum of improvement at each time was less than seen
for KeGFRsCr.
Fig 4. Clinical model enhancement by measured and calculated variables at 12h. A: serum creatinine (sCr), B: estimated GFR using sCr (KeGFRsCr) C:
plasma Cystatin C (pCysC), D: estimated GFR using pCysC (KeGFRpCysC).
doi:10.1371/journal.pone.0125669.g004
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After adjusting for the baseline score, IDI analysis showed that sCr did not improve the pre-
diction of DGF at any time (Table 2, Fig 4).
Although univariable analysis showed better performance by pCysC than sCr, pCysC did
not independently improve DGF prediction at any time (Table 2, Fig 4).
Comparison of KeGFRsCr and KeGFRpCysC
KeGFRpCysC was generally higher than KeGFRsCr at both 8h and 12h (Fig 2H). Optimal cut-off
points for the prediction of DGF for KeGFRsCr at 4h, 8h and 12h were, respectively 0, 4, and 5
mL/min/ 1.73 m2 (S1 Table). The optimal cut-off points were higher for KeGFRpCysC than
KeGFRsCr (S1 Table).
Sensitivity analyses
The predictive performance of KeGFRsCr, and of KeGFRpCysC, were robust to changes in the
methods for calculating MaxΔBc/d, with no significant differences in AUCs (S2 Table). The
main impact was to change modestly the optimal cut-offs of KeGFR for predicting DGF. De-
spite a difference in BSA between DGF and non-DGF patients (Table 1), expression of KeGFR
in mL/min similarly produced no significant difference in AUCs (S2 Table). However, the ap-
parent performance of all biomarkers including KeGFRsCr was improved by inclusion of 25 re-
cipients of live-donor kidneys (S4 Table).
Long-term correlation
KeGFRsCr at 12h was correlated to eGFR at 12 months (Spearman r = 0.30, p = 0.04). sCr,
pCysC, eGFRsCr, eGFRpCysC, and KeGFRpCysC were not significantly correlated to 12-month
eGFR.
Discussion
This study assesses the use of this novel method of estimating GFR under non-steady state con-
ditions [1] and demonstrates that the KeGFR formula predicts DGF within 4 hours of renal
transplantation. While the derivation of the formula has been explained elsewhere,[1], it has
not previously been evaluated in any patient cohort. The unadjusted eGFR did not improve
prediction of DGF, while AUCs for KeGFRsCr were greater than for sCr. Since comparing
AUCs has limited power to assess relative clinical utility [23,25], IDI analysis was used to evalu-
ate the added value KeGFRsCr provided over the baseline model [23]. In contrast to sCr alone
[23], KeGFRsCr independently enhanced the clinical model for DGF prediction at 4h, 8h, and
12h after transplantation and appears useful for early assessment of graft function.
The utility of pCysC and KeGFRpCysC was similarly evaluated. Consistent with previous re-
ports [7,13], AUCs for pCysC were fair [10] in transplant recipients and generally greater than
sCr. After accounting for the baseline model, pCysC did not significantly improve DGF predic-
tion. Although KeGFRpCysC was only evaluated at 8h and 12h, performance was similar to
KeGFRsCr.
While, for example, the cut-off of KeGFRsCr that predicted DGF at 4h, 8h or 12h with 90%
sensitivity lay between 0 and 7 mL/min/1.73m2 (S1 Table) the ideal diagnostic cut-off for any
test requires prospective evaluation, and depends on the relative importance of identifying true
positives (sensitivity) or true negatives (specificity), balancing the potential harms and benefits
of any consequent intervention.
Applying the KeGFR formula did not further improve DGF prediction for pCysC as much
as it did for sCr. At least three explanations are possible. Firstly, pCysC is less dependent on
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sex, race and body mass than sCr [26], thus unadjusted values require less “improvement” for
clinical utility. Secondly, pCysC values approach steady-state more rapidly than sCr, reflected
in the better agreement between KeGFR and eGFR for CysC than sCr at all timepoints. Thirdly,
extra-renal clearance of biomarkers affects estimated GFR most at low GFRs, such as seen here.
Extra-renal clearance has been estimated at 22mL/min/1.73m2 for CysC [12], versus<10mL/
min/1.73m2 for creatinine [27].
KeGFRsCr has several advantages over alternative approaches for identifying DGF. Firstly,
sCr is inexpensive, routinely measured post-transplant, and familiar to all. The formula is rela-
tively simple, calculation of KeGFR at any time requires only 2 values of sCr or pCysC. Indeed,
the entire analysis presented here rests upon 4 values of sCr and 3 values of pCysC for each pa-
tient. However, while most physicians evaluate post-operative changes in sCr, the approach to
changing sCr values is ad hoc. Chen proposed that use of the KeGFR formula in AKI could
standardise the approach to changing sCr values adding “a quantitative and visual dimension
to assessment of kidney function” [1]. Secondly, while sCr alone, and relative and absolute
change in sCr are inadequate for early DGF prediction [5,6], the KeGFRsCr formula reconciles
the absolute value of sCr with rate of change to estimate kidney function. Thus, within the first
half of the kinetic formula, “BC  eGFR
MeanBc
”, higher mean circulating biomarker concentrations pro-
duce lower KeGFR values. Within the second half, “ 1 24DBCDtMaxDBC=d
 
”, is a first order deriva-
tive of sCr (or pCysC) vs. time reflecting rate of change in sCr (or pCysC) analogous to the
relationship of distance vs. time and velocity. Here, larger falls in circulating biomarker con-
centrations (consistent with prompt allograft function) produce higher KeGFR values. Increas-
ing circulating biomarker values (negative values of ΔBc) produce lower KeGFR values.
Thirdly, unlike urinary biomarkers, interpretation of circulating biomarkers is not complicated
by transient anuria and the consequent failure to collect urine [13].
Limitations of this study include those underpinning the kinetic formula itself [1], and
those in study design. Since Bc cannot be collected continuously, the methodology borrows
from the ancient mathematical method of exhaustion to produce an estimated mean GFR over
time, rather than instantaneous real-time evaluation. Abrupt changes in GFR, e.g. due to renal
vein thrombosis, may not be recognized although similar limitations apply to clearance-based
GFR measurements using iothalamate or EDTA [4]. Circulating biomarker concentrations are
likely to be most affected by pre-operative dialysis and intra-operative fluid administration im-
mediately after transplantation. This may explain the poorer performance of KeGFRsCr at 4h
than at 8h and 12h.
The formula adopts mass balance principles [1,19] stipulating that change in the amount of
creatinine (or CysC) in the body over time, is equal to the amount of creatinine generated (or
CysC) minus the amount of creatinine (or CysC) excreted. The generation of KeGFR< 0 seen
in some patients (e.g. nine patients for KeGFRsCr at 12h) probably reflects either an underesti-
mate of MaxΔBc/d in the affected patients [1] or error in the measurement of the relevant bio-
marker at one or both times, inherent to all assays.
There are several potential sources of inaccuracy in the estimation of MaxΔBc/d. Firstly, the
methodology does not account for factors like perioperative muscle wasting affecting creatinine
generation, or corticosteroid administration [26] affecting CysC generation. Secondly, Chen,
like several authors [19,28], assumed an equivalence of CrCl and GFR. This leads to the inaccu-
rate assumption that any sCr multiplied by the corresponding steady-state eGFR (or
pCysC × eGFR) is equivalent and indicates daily creatinine (or CysC) production [1]. Unlike
the Cockroft-Gault formula, derived from measured Cr excretion [8,16,29], back calculation
from the empirical CKD-EPI formula [14,30] produces lower estimates of creatinine produc-
tion at higher values of sCr. For consistency, we arbitrarily used the value of sCr (or pCysC) at
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4h to estimate creatinine (or CysC) production and Bc×eGFR. Despite the theoretical limita-
tions, the sensitivity analysis suggested that the receiver operator characteristics of KeGFR
were robust to different assumptions of creatinine or CysC production. Thirdly, the one-com-
partment kinetic model used might modestly mischaracterize the distribution of creatinine or
CysC [3,19]. Fourthly, calculations do not account for changing plasma volumes and hence Vd
[1,8]. To incorporate these factors into calculations would require repeated patient weighing
after surgery or very accurate fluid balance charts, strategies with inherent practical limitations
and imprecision [3,31].
This is a retrospective analysis. Future prospective studies would ideally obtain pCysC at 0h,
allowing evaluation of KeGFRpCysC at 0h–4h; the absence of these results may obscured the
possible superiority of KeGFRpCysC at this early time. Despite the weaknesses of current meth-
ods of measuring GFR in non-steady state conditions it would be useful to compare measured
GFR to KeGFR, particularly since KeGFRsCr yielded higher values and diagnostic cut-offs than
KeGFRsCr. A further limitation is the modest cohort size. A comprehensive risk model requires
external validation and a much larger data set than available here, and this study cannot resolve
which of multiple possible clinical risk models [8,29,32] is best. Although the baseline model
adjusts for donation after cardiac death in calculating risk of DGF, a meaningful comparison
recipients of DCD-kidneys and donation-after-brain-death-kidneys was not possible. This is
not an attempt at validation, but rather an exploration of whether a new biomarker, kEGFR,
provides independent prediction of outcome. In this proof of concept study, kEGFR indepen-
dently predicted DGF adding to a validated risk model. It remains necessary to undertake a
large multicentre validation study, potentially incorporating more complex patients and great-
er variation in fluid management and immunosuppressive approaches that impact renal blood
flow and clearance.
Two semantic issues warrant attention. Firstly, defining DGF by dialysis requirement has
the advantage of simplicity [30], is associated with increased rejection and graft loss [3], under-
lies the clinical risk prediction model used here [8], and is the most common method [3]. How-
ever the definition is arguably subjective, and any future interventional studies should be
powered to examine hard endpoints such as long-term graft function and graft-survival. Sec-
ondly, because DGF is mainly the consequence of perioperative ischaemia-reperfusion injury,
it is debatable whether DGF is “predicted” or simply “detected” before dialysis is initiated. We
have used the term “predicted” to emphasise that early identification of risk will facilitate early
and appropriate triaging of affected patients.
In conclusion, applying the KeGFRsCr, derived from readily obtainable sCr results, im-
proved DGF prediction. Like sCr, KeGFR can be inexpensively measured, and clinical applica-
tion would easily facilitated with a web-based calculator. Use of this equation might facilitate
trials of early intervention aimed at ameliorating ischemia-reperfusion injury.
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transplant using specific values of sCr, pCysC KeGFRsCr and KeGFRpCysC. Key: NPV: nega-
tive predictive value; PPV: positive predictive value. Cut-off values shown were those nearest
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